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Abstract
Background—Systemic blockade of Tissue Factor (TF) attenuates acute lung injury (ALI) in
animal models of sepsis but the effects of global TF deficiency are unknown.
Hypothesis—We used mice with complete knockout of mouse TF and low levels (~1%) of
human TF (LTF mice) to test the hypothesis that global TF deficiency attenuates lung
inflammation in direct lung injury.
Methods—LTF mice were treated with 10 μg of lipopolysaccharide (LPS) or vehicle
administered by direct intratracheal (IT) injection and studied at 24 hours.
Results—Contrary to our hypothesis, LTF mice had increased lung inflammation and injury as
measured by bronchoalveolar lavage cell count (3.4 × 105 WT LPS versus 3.3 × 105 LTF LPS,
p=0.947) and protein (493 μg/ml WT LPS versus 1014 μg/ml LTF LPS, p=0.006),
proinflammatory cytokines (TNF-α, IL-10, IL-12, p<0.035 WT LPS versus LTF LPS) and
histology compared to wild type mice. LTF mice also had increased hemorrhage and free
hemoglobin in the airspace accompanied by increased oxidant stress as measured by lipid
peroxidation products (F2-Isoprostanes and Isofurans).
Conclusions—These findings indicate that global TF deficiency does not confer protection in a
direct lung injury model. Rather, TF deficiency causes increased intra-alveolar hemorrhage
following LPS leading to increased lipid peroxidation. Strategies to globally inhibit tissue factor
may be deleterious in patients with ALI.
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INTRODUCTION
Activation of the extrinsic coagulation cascade through upregulation of tissue factor (TF)
dependent procoagulant activity has been implicated in the pathogenesis of both acute and
chronic lung injury and may contribute to lung inflammation. In the setting of acute lung
injury, TF protein is elevated both systemically 1 and locally 2 within the airspaces of the
lung. Several studies have shown that systemic blockade of TF activity in the setting of
sepsis attenuates organ dysfunction and acute lung injury. He et al showed that systemic
blockade of TF in an intestinal ischemia-reperfusion model attenuated the severity of lung
injury, leak and inflammation. 3 Welty-Wolf and colleagues found that systemic blockade of
TF using either a TF blocking antibody 4 or active site inactivated factor VIIa 56 attenuated
lung injury in an Eschericia coli model of sepsis in baboons. This group further reported that
systemic blockade of TF activity attenuated lung inflammation in a model of direct lung
injury using intratracheal (IT) lipopolysaccharide (LPS). 7 In summary, there is ample
evidence that systemic inhibition of TF activity attenuates lung inflammation and injury
induced by both direct and indirect insults. Despite this, the mechanisms by which systemic
blockade of TF activity modulates coagulant and inflammatory processes in the lung
environment are not clear. Studies by our group and others have shown that intra-alveolar
fibrin deposition is modulated locally within the airspace by resident lung cells including the
lung epithelium 2, 8–10, but effects of systemic TF inhibition on lung coagulation remain
incompletely understood.
Given the compelling evidence that systemic blockade of TF ameliorates lung injury in
indirect lung injury (sepsis) models but the paucity of data on the effects of global inhibition
of TF in the response to acute lung inflammation caused by direct lung injury, we designed a
series of experiments to test the hypothesis that global TF deficiency is protective in a model
of direct lung inflammation. We used genetically manipulated mice that have global absence
of mouse TF but express human TF protein at levels that are 1% of endogenous levels to
prevent embryonic lethality (LTF mice). 11 Importantly, these mice have a hemostatic defect
and exhibit spontaneous hemorrhage in various tissues, including the lung.12 Histologic
analysis of lungs from 6 month old LTF mice showed extensive hemosiderin deposition
suggestive of chronic lung hemorrhage. 12 Despite evidence of chronic lung hemorrhage in
LTF mice, these mice were protected in an indirect lung injury (endotoxemia) model 13 with
increased survival following systemic administration of endotoxin compared to littermate
controls. How genetic deficiency of TF affects lung specific coagulation and inflammation is
unknown. Here we present the results of our experiments using a model of direct lung




All experiments were approved by the Vanderbilt Institute for Animal Care and Use
Committee. Transgenic LTF mice on a C57/BL6 background were used for these
experiments. The mice were generated as previously described by Parry et al 11 and
expressed human TF mRNA at ~1% of levels measured in normal wild type mice. Mice that
were heterozygous for the murine tissue factor (mTF) gene and containing the human tissue
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factor (hTF) minigene were bred in order to obtain low TF mice (mTF−/−, hTF+, N=51) and
wild type littermate controls (mTF+/+, hTF−, N=38).
Mouse Experimental Protocol and Tissue Collection
Mice were anesthetized with isoflurane and instilled by direct intratracheal (IT) injection
with 100μl of 100 μg/ml Lipopolysaccharide (Escherichia Coli, LPS, Sigma, St. Louis,
MO), 100μl of PBS (control) (Mediatech, Manassas, VA) and with 100nM recombinant
murine TF (mTF) (R&D Systems, Minneapolis, MN) for selected experiments as described
by Su et al. 14 After 24 hours, mice were euthanized by intraperitoneal injection of 200μl of
a 23% solution of Sleepaway (Fort Dodge Animal Health, Fort Dodge, IA). All data
represent 2–12 mice per group depending on the experiment. Measurements were done
using all available samples were used for each measurement. Limitations in sample volumes
did not allow every measurement to be made in every experimental animal. BAL was
obtained by instilling 900μl 0.9% NaCl and gently aspirating the fluid. BAL was
centrifuged at 1000g for 10 minutes and supernatant was collected and frozen at −80°C. The
lungs were removed, flash frozen in liquid nitrogen and stored at −80°C.
BAL Cell Count and Differential
Manual cell counts using a hemacytometer and cytospins/differentials were completed with
fresh BAL fluid. Cytospins were stained with Hema 3 staining kit (Thermo Fisher
Scientific).
Lung mTF Western
Protein was extracted from frozen lung tissue using a radioimmunoprecipitation assay
(RIPA) buffer containing 50mM Tris, 100mM NaCl, 1mM EDTA, 0.5% sodium
deoxycholate, 1% Triton-x-100, and 0.1% SDS with Protease Inhibitor Cocktail (Roche,
Indianapolis, IN) and kept on ice. Lung tissue was homogenized in 1ml of RIPA buffer and
spun at 13,000 rpm at 4°C for 5 minutes. Supernatant was removed and placed in NuPAGE
LDS sample buffer (Invitrogen, Carlsbad, CA) with 100mM DTT, vortexed, boiled for 5
minutes and stored at −80°C. Protein was separated by SDS-PAGE, using 10%
polyacrylamide gels (BioRad, Hercules, CA), electro blotted onto a PVDF membrane
(Millipore, Burlington, MA) and blocked with Odyssey Blocking Buffer (LI-COR, Lincoln,
NB), washed with PBS 0.1% Tween, and incubated with anti-TF primary antibody (R&D
Systems, Minneapolis, MN) against mTF at 1:1000 overnight at 4°C. Blots were washed and
incubated with secondary antibody (LI-COR) at 1:15000 for 1 hour at room temperature and
visualized with the Odyssey infrared imaging system (LI-COR). Densitometric
measurements were collected. Actin was used as a protein loading control.
Lung hTF PCR
RNA was isolated from approximately 30mg of lung tissue with the Pure Link RNA Mini
Kit (Invitrogen) with Trizol. cDNA was synthesized using the SuperScript VILO kit
(Invitrogen). Real Time-PCR assay was perfomed using Taqman Universal Master Mix and
commercially available primers/probes for human TF (Applied Biosystems) on a Step-One
PCR instrument (Applied Biosystems).
mTF Immunostaining
Paraffin embedded lung sections were de-paraffinized prior to antigen retrieval (Retrievit-6,
Innogenex, San Ramon, CA) for 20 minutes in a rice cooker. Slides were rinsed with DI
water and incubated for 20 minutes in 0.3% H2O2 in cold methanol then rinsed and blocked
(Powerblock, Biogenex, Fremont, CA and 0.4% Triton) for 15 minutes in a humid
environment. Slides were rinsed and incubated overnight at 4°C with 1:200 goat polyclonal
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anti-TF Ab (R&D Systems, Minneapolis, MN), rinsed, and incubated with a biotinylated
rabbit anti-goat secondary antibody (Innogenex, San Ramon, CA) for 20 minutes at room
temperature. Slides were developed with NovoRed (Vector, Burlingame, CA) for 30
seconds and counterstained with Methyl Green for 10 seconds.
Lung Wet-to-Dry Weight Ratio
The left lung was removed and placed on a piece of pre-weighed aluminum foil. The foil +
lung was weighed and placed in an 80°C oven for 2 days. The foil + lung was weighed again
and the ratio was calculated ([lung+foil before drying]/[lung+foil after drying]).
BAL Clot Time Measurements
Clot time was measured using a mechanical clot detection system (STart4 Coagulometer;
Diagnostica Stago, Asnieres, France). Briefly, 25 μl of BAL was warmed for 15 min at
37°C. Samples were then incubated with 25 μl of pooled citrated mouse plasma
(Bioreclamation, East Meadow, NY). Clot time was determined as recalcification time
following the addition of 25 μl of 50 mM calcium chloride. Measurements were done in
duplicate.
BAL Protein and Cytokine Measurements
Protein was measured in BAL using the BCA protein assay according to manufacturers
instructions (Pierce, Rockford, IL). Cytokines were measured by electrochemiluminescence
in a mouse 7-plex proinflammatory cytokine assay according to manufacturers instructions
(Meso Scale Discovery, Gaithersburg, MD).
Lung Histology and Scoring
Formalin fixed and paraffin embedded lung sections were stained with H+E. 10 images were
captured at 40x power across 2 lobes of each lung. Each images was scored on a 5 point
scale modified from Frank, et al 15 for septal thickening, edema, inflammation, and
hemorrhage in a blinded fashion. The scores for each parameter were averaged for the 10
images and the averages were added to generate a total lung injury score.
Free Hemoglobin Measurements
Free hemoglobin was measured in undiluted cell free pulmonary edema fluid collected as
previously described 2 from critically ill mechanically ventilated patients with acute lung
injury (ALI) or control patients with severe hydrostatic pulmonary edema (HYDRO) using
the low hemoglobin analyzer from HemoCue (Cypress, CA) according to manufacturer’s
instructions. Human studies were approved by the Vanderbilt Institutional Review Board.
Lung Isoprostane and Isofuran Measurements
F2-IsoPs and IsoFs were quantified in mouse lung homogenates and human BAL by stable
isotope dilution gas chromatography/negative ion chemical ionization mass spectrometry
(GC/NICI/MS) as described previously. 16, 17
Statistical Analysis
Non-normally distributed data were natural log transformed prior to statistical analysis and
are displayed as boxplots or dot plots. Normally distributed data are displayed as bar graphs
showing mean and SEM. Comparison of 3 or more groups was done using one way
ANOVA with post hoc Tukey test. Comparison of 2 groups was done using a Students t test
for normally distributed or transformed data. Percent body weight loss was non-normally
distributed but could not be log transformed because the majority of the values were
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negative numbers. For this analysis, a Kruskall-Wallis test was performed followed by
pairwise Mann-Whitney U tests for comparisons between groups. All analyses were done
with SPSS software version 19 for Macintosh. For all analyses, p<0.05 was considered
statistically significant.
RESULTS
TF levels and coagulation in LTF mice
Murine TF, measured by Western blot, was present in low levels in lung homogenates in
wild type mice and modestly increased following treatment with IT LPS (p=0.116 WT PBS
versus WT LPS) (Figure 1A and D). LTF mice had no detectable mTF in either treatment
group. Immunostaining showed mTF protein lining the airspace in WT mice (Figure 1B) but
no detectable lung staining for TF in LTF mice (Figure 1C). Because of very low levels of
expression, human TF protein could not be detected by Western blotting and expression was
measured in low TF mice by PCR. hTF mRNA was detectable in LTF mice but was not
detected in WT mice and LPS treatment had no effect on hTF expression (data not shown).
In WT mice, clot time decreased with LPS treatment compared to PBS treatment (Figure
1E) consistent with induction of TF-dependent procoagulant activity in the alveolar
compartment. In LTF mice, BAL clot time was prolonged compared to WT mice (Figure
1E) in both treatment groups consistent with the deficiency of TF and was not significantly
shortened in response to LPS treatment. Both WT and LTF mice lost a significant amount of
body weight 24 hours after treatment with IT LPS (Figure 1F).
LTF mice are not protected from lung inflammation induced by IT LPS
Both WT and LTF mice had increased BAL total cell counts 24 hours after IT LPS (Figure
2A). There was more variability in the inflammatory response in LTF mice compared to WT
with some LTF mice exhibiting an exaggerated inflammatory response, one third of the LTF
mice had BAL cell counts that were higher than the highest counts in wild type mice. In WT
mice treated with LPS, neutrophils predominated (88% neutrophils, 12% macrophages)
while LTF mice had a higher percentage of macrophages (45% neutrophils, p=0.513 versus
WT LPS, 55% macrophages, p=0.513 versus WT LPS) (Figure 2B). In addition, LPS treated
low TF mice had significantly increased BAL levels of IL-10, IL-12 and TNF-α and a non-
significant increase in IFN-γ, IL-1β, IL-6 and IL-8 (Table 1). There was also a modest
increase in IL-6 and IL-8 in PBS treated LTF mice compared to WT.
LTF mice have increased pulmonary edema in response to IT LPS
Pulmonary capillary leak was assessed by lung wet-to-dry weight ratios (Figure 3A) and
total BAL protein (Figure 3B). Both WT and LTF mice had modest but non-significant
increases in wet-to-dry weight ratio following treatment with IT LPS without a significant
difference between genotypes. BAL protein, however, was increased in response to IT LPS
in both groups and LTF mice had BAL protein levels that were 2-fold higher than WT mice.
WT and LTF LPS treated mice have increased histologic lung injury
The degree of lung injury was assessed histologically using a 5 point scoring system in a
blinded fashion. Both WT (Figure 4A) and LTF (Figure 4B) mice had increased histologic
evidence of lung injury 24 hours after IT LPS treatment (Figure 4C and E). LTF mice had
significantly more alveolar hemorrhage (Figure 4D and E, Figure 5A) compared to WT
mice.
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LTF mice have higher levels of free hemoglobin in the lung and elevated isoprostanes and
isofurans compared to WT mice
Because Low TF mice were not protected from IT LPS induced lung inflammation and had
increased bleeding into the airspaces, we hypothesized that release of free hemoglobin into
the airspaces might be contributing to lung injury and inflammation in the low TF mice.
Low TF mice treated with IT LPS had higher levels of free hemoglobin in the cell free BAL
than WT mice (Figure 5B). To test whether the free hemoglobin is contributing to lung
injury through increased oxidant stress we measured total lung isoprostanes (Figure 5C) and
isofurans (Figure 5D) in lung homogenates. LPS treated LTF mice had higher levels of both
isoprostanes and isofurans in the lung compared to LPS treated WT mice. To test whether
these findings are applicable to human disease, we measured free hemoglobin in undiluted
pulmonary edema fluid from patients with acute lung injury (ALI) compared to control
patients with severe hydrostatic pulmonary edema and found that free hemoglobin levels
were significantly elevated in patients with ALI (Figure 5E). Finally, to test whether free
hemoglobin in human lungs is associated with markers of lipid peroxidation we measured
BAL ispoprostanes and isofurans in sequential BAL aliquots from 5 patients with diffuse
alveolar hemorrhage (Figure 5F). In patients with alveolar hemorrhage, sequential aliquots
of BAL fluid are progressively bloodier. As the aliquot number increased, BAL isoprostane
and isofuran levels increased.
Effects of mTF replacement in LTF mice
LTF mice were treated with LPS or LPS plus recombinant murine tissue factor (mTF) and
analyzed at 24 hours. LTF mice treated with mTF had visibly decreased BAL hemorrhage
(Figure 6A) and a shortened clot time (Figure 6B) suggesting that replacement of TF into the
airspace partially restored TF procoagulant activity. mTF treatment attenuated lung
permeability induced by IT LPS as measured by BAL protein (Figure 6C) but did not affect
inflammatory cell influx (Figure 6D).
DISCUSSION
Contrary to our hypothesis, global deficiency of TF is not protective in a model of direct
lung inflammation. LTF mice have influx of inflammatory cells into the lung in response to
IT LPS with BAL cell counts that are comparable to WT mice. In addition, LTF mice have
increased BAL cytokines, histologic severity of lung injury and alveolar capillary barrier
permeability compared to WT mice. These findings are in distinct contrast to prior reports
that systemic inhibition of TF was protective in either a direct or indirect model of acute
lung injury 4–7. All of these studies suggest that inhibition of coagulation is protective in
models of acute lung injury. While the increases in lung injury in LTF mice in our studies
are modest, the fact that our findings contradict prior work in this field is particularly
interesting.
TF mediated coagulation is upregulated in the lung in the setting of inflammation and
injury 2, 18–20 but whether TF in the lung is protective or injurious is not completely
understood. Other studies have shown that TF inhibition and deficiency protects against lung
injury. One important difference between our study and previous reports is that we used a
model of global TF deficiency while the previous studies have administered pharmacologic
TF inhibitors systemically, which may or may not have modulated coagulation in the lung.
We have previously shown that coagulation is modulated locally by the lung
epithelium. 2, 8, 9, 21 Because coagulation is regulated locally in the airspace independent of
the circulation, modulation of coagulation using inhibitors delivered systemically as in the
previous studies might have very different effects compared to global TF deficiency. In the
current study, global TF deficiency did not protect against lung inflammation in response to
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a direct insult. Interestingly, the same LTF mice treated with systemic LPS have decreased
systemic inflammation and improved survival compared to control mice treated with LPS.22
These findings suggest that mice with global TF deficiency respond quite differently to local
versus systemic inflammatory insults.
One observation that we made in our initial experiments was that the BAL from LTF mice
appeared blood tinged while the BAL from WT mice was clear. LTF mice are known to
have chronic hemorrhage into the lungs 12 and might be expected to have increased
hemorrhage in response to injury. In addition, LTF mice also had significantly increased
BAL protein and modestly increased lung wet to dry weight ratios which may have
contributed to increased bleeding in the lungs. The discrepancy between BAL protein and
wet to dry weight ratios may be explained by the relatively mild epithelial injury in LTF
mice that allows for preserved alveolar fluid clearance in the setting of increased
permeability. To understand whether blood in the lung augmented lung inflammation, we
studied the potential injurious effects of bleeding into the lungs in LTF mice. In addition to
intact RBCs in the airspace as seen on histology, LTF mice had red-tinged BAL fluid after
the removal of cellular components, suggestive of free hemoglobin. To quantify this
observation we measured free hemoglobin in cell free BAL in both WT and LTF mice and
found that only 13% of WT mice had any detectable free hemoglobin in the BAL after LPS
treatment while 41% of LTF mice had measureable levels (Figure 5B). Since free
hemoglobin is a potent oxidant and could potentially contribute to lung inflammation and
injury, we measured lung isoprostanes and isofurans as a marker of oxidant-mediated lipid
peroxidation and found that both were elevated in the lungs of LTF mice compared to WT
(Figure 5C, D). Thus, one potential mechanism whereby LTF mice have increased lung
inflammation and injury is through the harmful effects of free hemoglobin. Free hemoglobin
is a potent inducer of oxidant stress. Free hemoglobin oxidizes lipids and can cause
extensive cell damage. 23 Hemoglobin can potentiate vascular injury induced by oxidized
LDL 24 or activated neutrophils. 25 Although cell free hemoglobin has been implicated in
the pathogenesis of transfusion related acute lung injury, 26, 27 little is know about the direct
effects of free hemoglobin in the airspace. Our data suggest that free hemoglobin in the
airspace may be injurious by inducing lipid peroxidation since LTF mice have both elevated
levels of free hemoglobin and an increase in markers of lipid peroxidation.
Elevated free hemoglobin in the airspace is not unique to this mouse model of acute lung
injury. To determine the clinical significance of our findings, we measured free hemoglobin
or isoprostanes/isofurans in the airspaces of two patient cohorts. Patients with acute lung
injury had very high levels of free hemoglobin in the airspace compared to critically ill
mechanically ventilated controls with cardiogenic pulmonary edema. Patients with diffuse
alveolar hemorrhage had progressively increasing BAL isoprostanes and isofurans as their
sequential BAL aliquots become more bloody. These findings suggest that liberation of free
hemoglobin into the airspace and intraalveolar lipid peroxidation may be important
mechanisms of clinical acute lung injury.
To confirm that the effects of LPS in LTF mice were a result of TF deficiency, we repeated
our experiments in LTF mice and reconstituted lung TF by co-injection of a recombinant
murine TF protein with LPS. In these experiments, TF replacement attenuated lung
hemorrhage and permeability induced by LPS and augmented lung coagulation. However,
mTF replacement had no effects on lung inflammation. These data suggest that free
hemoglobin mediates the increased lung permeability and lipid peroxidation in LTF mice
and can be reversed by TF replacement while TF replacement does not mediate changes in
inflammation. Others have shown that circulating free hemoglobin mediates vascular
permeability. In a murine model of sickle cell disease with extensive intravascular
hemolysis, free hemoglobin induces endothelial permeability in the lungs. 28 Our study is
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the first to suggest that free hemoglobin in the airspace may be a potent mediator of lung
permeability. Although we have not measured circulating free hemoglobin in our studies the
fact that replacement of TF in the airspace attenuates lung hemorrhage as well as
permeability suggest that it is the intra-alveolar hemoglobin that is mediating these effects.
Admittedly our study did not specifically test the independent effects of free hemoglobin so
it may be that free hemoglobin is simply a marker of increased permeability. In addition to
it’s role in modulating free hemoglobin, the effects of TF deficiency on lung inflammation
may be mediated through a different mechanism such as loss of PAR-2 signaling in LTF
mice or lack of adequate intra-alveolar TF replacement. Understanding the mechanism of
LTF effects on lung inflammation will be the focus of future studies.
The study has some limitations. First, by using mice with a global TF deficiency we were
unable to identify which cell type or types are most critically involved in the lung response
to IT LPS. However, our results do show that global TF deficiency does not protect against
direct lung injury, and in fact enhances several indices of acute lung injury including BAL
cytokines as well as BAL protein and histologic injury. Interestingly, LTF mice may have
increased susceptibility to even mild insults. In our LTF mice treated with PBS we observed
increased BAL IL-6 and IL-8, higher levels of BAL protein, and mild increases in histology
score and BAL cell counts although not all of these findings were statistically significant.
This response to a very mild insult, IT PBS, highlights the critical nature of TF in limiting
lung injury and inflammation. Second, our studies were not designed to test whether the
effects of TF deficiency are mediated through the procoagulant function of TF or whether
the effects are modulated through noncoagulant functions of TF such as signaling effects
through protease activated receptors. Along these lines, it is unknown whether human TF
can signal through mouse PAR-2. While it is possible that the human protein cannot signal
through murine PAR-2 we would not expect this to affect our results since we are studying
LTF mice which would be expected to have reduced PAR-2 signaling as a result of TF
deficiency. Our results do show that global TF deficiency leads to increased bleeding into
the lung and a concomitant increase in lung injury. Finally, although we have shown that
free hemoglobin and markers of lipid peroxidation are elevated in the lungs of LTF mice
there may be additional mechanisms that explain the increased lung inflammation seen in
these animals.
In summary, mice with a global deficiency of tissue factor are not protected from the effects
of IT LPS as they have modestly increased lung inflammation, injury and permeability
compared to LPS treated WT mice. Our data suggest that intra-alveolar bleeding in LTF
mice in response to IT LPS may contribute to lung injury through the oxidant effects of free
hemoglobin. Furthermore, we demonstrate that many of the indices of injury can be
attenuated with IT TF replacement. These findings are relevant to human acute lung injury
and highlight the complexity of coagulation pathways in the acutely injured lung. Two
clinical trials related to acute lung inflammation have been completed using recombinant
tissue factor pathway inhibitor (TFPI, Tifacogin®), one in severe sepsis 29 and one in severe
community acquired pneumonia. 30 Neither of these trials showed a clinical benefit of TFPI.
This study included patients with both direct and indirect causes of ALI and TF blockade
may have different effects depending on the cause of ALI. Furthermore, the specific roles of
TF in the lung and vascular compartment may be different as our TF replacement studies
might suggest. Future studies will focus on compartmentalized manipulation of the TF
pathway in both direct and indirect ALI.
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TF expression. Wild type mice have low but detectable levels of murine TF expression at
base line that increases following IT LPS treatment while murine TF levels are undetectable
in LTF mice. Panel A shows a representative western blot for murine TF and Panel D shows
densitometric quantification from 4 independent experiments. *p=<0.001 versus both wild
type groups. Panel B and C show immunostaining for murine TF (red/brown) in WT (B) and
LTF (C) mice 24 hours after IT LPS. While wild type mice have a shortened BAL clot time
in response to IT LPS (Panel E), LTF mice have a prolonged clot time that is not shortened
by IT LPS. *p<0.001 versus WT. Panel F shows weight change 24 hours after treatment
with LPS. *p<0.001 versus PBS treatment.
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Intratracheal LPS induces lung inflammation. Dot plot of BAL cell counts 24 hours after IT
LPS administration. BAL total cell count was increased in both wild type and low TF mice
compared to saline treated animals (Panel A). *p<0.005 versus PBS treatment by ANOVA
of log transformed data with post hoc Tukey test. Panel B shows median (IQR) total BAL
macrophage and neutrophil counts and percent counts.
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IT LPS increases lung edema. IT LPS causes a modest but non-significant increase in lung
wet to dry weight ratio (Panel A) but there are no differences between WT and LTF. In
contrast, BAL total protein is significantly increased by IT LPS (Panel B). *p<0.007 versus
WT PBS and LTF LPS groups, **p<0.007 versus all other groups.
Bastarache et al. Page 13














Lung histology 24 hours after IT LPS. IT LPS induced lung inflammation and injury in both
WT (Panel A) and LTF (Panel B) mice. LPS treatment increased lung injury in both
genotypes (Panel C) [*p<0.002 versus PBS treatment]. Lung hemorrhage was more severe
in LPS treated LTF mice compared to WT (Panel D) [*p<0.027 versus all other groups,**
p<0.019 versus all other groups]. Panel E shows the individual components of the score [*
p<0.05 vs PBS treatment in both genotypes, ** p<0.05 vs PBS treatment in both genotypes
and WT LPS treatment].
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Free hemoglobin and lipid peroxidation. LTF mice have increased alveolar hemorrhage
(Panel A) and increased free hemoglobin in BAL fluid (Panel B) both basally and in
response to IT LPS. LTF mice also have an increase in total lung isporostanes (Panel C) and
isofurans (Panel D) in response to IT LPS (*p<0.001 versus all other groups and **p<0.021
versus all other groups). Patients with ALI also have increased levels of free hemoglobin in
the lung compared to patients with hydrostatic edema (Panel E) (*p=0.007). In patients with
a diagnosis of alveolar hemorrhage, BAL isoprostanes and isofurans increase with
increasing aliqout number (Panel F).
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Effects of TF replacement in LTF mice. LTF mice were treated with 10μg LPS IT (N=4) or
10μg LPS + 100 nM recombinant mTF IT (N=5) and harvested at 24 hours. With the
administration of mTF, LTF mice had visibly reduced BAL hemorrhage (Panel A) and
significantly shortened BAL clot time (Panel B) compared to LPS treated mice that did not
receive recombinant TF. BAL total protein was higher in mice given mTF (Panel C) but
BAL cell counts did not differ (Panel D). (*p=0.011, **p=0.031).
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